Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.370
+0.070 (5.38%)
Apr 23, 2024, 10:50 AM EDT - Market open

Ikena Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
9.1615.6230.999.1913.75
Revenue Growth (YoY)
-41.35%-49.59%237.01%-33.15%-
Gross Profit
9.1615.6230.999.1913.75
Selling, General & Admin
24.9322.218.028.877.31
Research & Development
59.6564.3247.1144.8524.94
Operating Expenses
84.5886.5265.1253.7132.25
Operating Income
-75.42-70.9-34.14-44.52-18.49
Other Expense / Income
-7.09-2.14-0.02-0.26-1.68
Pretax Income
-68.33-68.77-34.12-44.26-16.82
Income Tax
-0.160000
Net Income
-68.17-68.77-34.12-44.26-16.82
Shares Outstanding (Basic)
42362833
Shares Outstanding (Diluted)
42362833
Shares Change
15.33%29.32%911.88%4.43%-
EPS (Basic)
-1.63-1.90-1.22-16.00-6.35
EPS (Diluted)
-1.63-1.90-1.22-16.00-6.35
Free Cash Flow
-80.16-75.54-62.01-38.5947.61
Free Cash Flow Per Share
-1.92-2.09-2.22-13.9617.98
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-823.33%-453.99%-110.18%-484.22%-134.46%
Profit Margin
-744.17%-440.29%-110.10%-481.36%-122.28%
Free Cash Flow Margin
-875.08%-483.67%-200.14%-419.75%346.19%
EBITDA
-65.59-66.73-32.4-42.99-16.7
EBITDA Margin
-716.09%-427.27%-104.56%-467.61%-121.39%
Depreciation & Amortization
2.732.031.721.260.12
EBIT
-68.33-68.77-34.12-44.26-16.82
EBIT Margin
-745.94%-440.29%-110.10%-481.36%-122.28%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).